Bicycle Therapeutics (BCYC) Accumulated Expenses (2018 - 2026)

Bicycle Therapeutics' Accumulated Expenses history runs 9 years deep, the most recent figure standing at $40.1 million for Q1 2026.

• Quarterly Accumulated Expenses rose 18.04% year-over-year to $40.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40.1 million (up 18.04% YoY) and the FY2025 annual result came in at $17.0 million, down 58.78% from the prior year.
• Accumulated Expenses was $40.1 million for Q1 2026 at Bicycle Therapeutics, up from $17.0 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $44.5 million in Q2 2025 and bottomed at $2.7 million in Q1 2022.
• A 5-year average of $20.4 million and a median of $17.0 million in 2022 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2024 — Accumulated Expenses surged 494.27% — and 2025, when it slumped 58.78%.
• Bicycle Therapeutics' Accumulated Expenses stood at $26.5 million in 2022, then tumbled by 49.36% to $13.4 million in 2023, then surged by 207.94% to $41.2 million in 2024, then plunged by 58.78% to $17.0 million in 2025, then surged by 136.02% to $40.1 million in 2026.
• Business Quant data shows BCYC's Accumulated Expenses at $40.1 million in Q1 2026, $17.0 million in Q4 2025, and $14.9 million in Q3 2025.